Alzheimer's-focused Administrative Supplements for NIH Grants that are not focused on Alzheimer's disease.

NIH 补助金的重点是阿尔茨海默病的行政补充，但不重点是阿尔茨海默病。

• 批准号: 10121141
• 负责人: Thomas J Bell
• 金额: $ 35.02万
• 依托单位: NATIONAL DISEASE RESEARCH INTERCHANGE
• 依托单位国家: 美国
• 财政年份: 1989
• 资助国家: 美国
• 起止时间: 1989-01-09 至 2023-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10121141
• 关键词: Address; Administrative Supplement; Affect; Age; Alzheimer' s Disease; Alzheimer' s disease related dementia; American; Area; Award; Awareness; Biological Models; Biomedical Research; Blood; Brain; Caregivers; Clinical; Collection; Communities; Complex; Consent; Custom; Data; Dementia; Development; Diagnosis; Diagnostic; Disease; Drug Industry; Eligibility Determination; Ensure; Etiology; Exhibits; Experimental Designs; Experimental Models; Foundations; Functional disorder; Funding; Future; Generations; Grant; Healthcare Systems; Human; Human Activities; Industry; Investigation; Lead; Liquid substance; Methodology; Methods; Monitor; National Institute on Aging; Neurodegenerative Disorders; Neurologic; Organ; Parents; Participant; Pathogenesis; Patients; Performance; Play; Population; Principal Investigator; Procedures; Provider; Recommendation; Recording of previous events; Recovery; Reporting; Reproducibility; Research; Research Personnel; Research Priority; Resources; Scientific Advances and Accomplishments; Scientist; Services; Shipping; Site; Source; Standardization; Techniques; Tissue Banks; Tissues; Training; United States National Institutes of Health; Work; cohort; effective therapy; experience; experimental study; human tissue; improved; interest; invention; member; mind control; nervous system disorder; outreach; parent grant; preservation; programs; recruit; success; symposium; tissue resource; translational study; treatment strategy; trend; web site

Program Director/Principal Investigator (Last, First Middle): Bell, Thomas J. Project Summary: The development of effective treatments or cures for a wide range of diseases requires translational studies that are directly relevant to human pathophysiology. The use of human biospecimens plays a key role in accelerating scientific discoveries in neurological research by providing scientists with a direct experimental model system to advance understanding of pathogenesis and treatment of neurological disease, including Alzheimer's disease and related dementias (AD/ADRD). To address several complex issues facing AD/ADRD research, including disease etiology as well as the development of improved diagnostics and treatment strategies, investigators require access to a unique human tissue resource that could provide rigorous and uniform collection of human biospecimens from defined cohorts of both post mortem AD/ADRD donors and living AD/ADRD patients to yield consistent and reproducible experimental results for inventive and groundbreaking studies. As a leading human tissue provider for the biomedical research community, the National Disease Research Interchange (NDRI) is a 501(c)(3), not-for-profit organization that remains at the forefront of coordinating biospecimen procurement to match the needs of advancing scientific experimental methodologies, enabling cutting-edge research. For over 30 years, NDRI has received NIH funding for the parent award to this administrative supplement, the Human Tissue and Organs for Research Resource (HTORR) Grant Number: U420DO1158. To address the high priority areas of research for AD/ADRD that require both post mortem and living patient biospecimen collection that are beyond the scope of HTORR, NDRI is expanding their capabilities to create a new resource, the AD/ADRD Human Biospecimen Resource (ADBR), funded by the active award 3U42OD011158-28S3. In Program Year 2 of the ADBR, NDRI continued to lead the development of the ADBR Advisory Council to obtain ongoing recommendations regarding biospecimen collection and distribution for the ADBR that align with an unmet or under represented need in the field. For the current proposal to continue the progression of the ADBR, NDRI will: 1) identify and authorize/consent distinct cohorts of non-diseased and AD/ADRD post mortem donors 2) coordinate the recovery of AD/ADRD biospecimens, 3) distribute biospecimens and donor data to investigators or store biospecimens to support future high priority area studies, and 4) monitor the performance of the ADBR and maintain guidance for the resource from an ADBR Advisory Council. In doing so, the biospecimen collection and preservation methods will be optimized to the experimental hypotheses and procedures for each ADBR study using NDRI's experience in coordinating standardized procurement, processing, preservation and shipping methods and maintaining industry best practices and standards regarding the donation of human tissue for research. The overall objective of the ADBR is to provide approved investigators with biospecimens from defined cohorts of AD/ADRD and non-diseased control post mortem donors, to support the generation of high-quality, reproducible data for the advancement of AD/ADR research. Relevance: As the most common cause of dementia, AD is a devastating, progressive neurodegenerative disease that affects over 5.7 million Americans (Alzheimer's Association et al, 2018) and has a significant burden on the US healthcare system as well as caregivers. As of yet, there are no disease-modifying treatment options available for AD/ADRD patients, making this a high priority for the research community. The objective of this proposal is to provide biospecimens from post mortem AD/ADRD donors, as well as non- diseased control donors for the AD/ADRD Human Biospecimen Resource (ADBR) that are suitable to support critical lines of investigation that address high priority needs and key issues in the field. OMB No. 0925-0001/0002 (Rev. 01/18 Approved Through 03/31/2020) Page Continuation Format Page

项目主任/主要研究者（最后，第一中间）：贝尔，托马斯J。 项目概要： 开发有效的治疗或治愈多种疾病的方法需要转化研究， 与人类病理生理学直接相关。人类生物标本的使用在加速 通过为科学家提供直接的实验模型系统， 深入了解神经系统疾病的发病机制和治疗，包括阿尔茨海默病 和相关痴呆（AD/ADRD）解决AD/ADRD研究面临的几个复杂问题，包括 疾病的病因学以及改进的诊断和治疗策略的发展， 需要获得独特的人体组织资源， 从尸检AD/ADRD供体和活体AD/ADRD患者的规定队列中采集生物标本， 一致和可重复的实验结果，用于创造性和开创性的研究。作为一个人类领袖 作为生物医学研究界的组织提供者，国家疾病研究交流中心（NDRI）是一个 501（c）（3），非营利组织，仍然处于协调生物标本采购的最前沿， 满足推进科学实验方法的需求，实现尖端研究。超过 30年来，NDRI已经收到了NIH的资助，作为对这一行政补充的母基金， 研究资源组织和器官（HTORR）授权编号：U420 DO 1158。为了解决高度优先的 AD/ADRD的研究领域需要死后和活体患者生物标本采集， 在HTORR的范围之外，NDRI正在扩展他们的能力，以创建一种新的资源，即AD/ADRD 人类生物标本资源（ADBR），由主动奖3U 42 OD 011158 - 28 S3资助。在程序年2 作为ADBR的一部分，NDRI继续领导ADBR咨询理事会的发展， 关于ADBR的生物标本采集和分发的建议， 外地的需求不足。对于目前继续推进ADBR的建议，NDRI 将：1）识别并授权/同意不同队列的非患病和AD/ADRD死后供体2） 协调AD/ADRD生物标本的回收，3）将生物标本和供体数据分发给研究者 或储存生物样本，以支持未来的高优先级区域研究，以及4）监测ADBR的性能 并维护ADBR咨询理事会对资源的指导。在此过程中， 并根据每个ADBR的实验假设和程序优化保存方法 利用NDRI在协调标准化采购、加工、保存和运输方面的经验进行研究 方法和维护行业最佳实践和标准，关于捐赠人体组织， research. ADBR的总体目标是为批准的研究者提供来自定义的 AD/ADRD和非疾病对照死后供体的队列，以支持产生高质量， 为AD/ADR研究的进步提供可重复的数据。 相关性：作为痴呆症最常见的原因，AD是一种破坏性的、进行性的神经退行性疾病， 影响超过570万美国人的疾病（阿尔茨海默氏症协会等，2018）， 美国医疗保健系统以及护理人员的负担。到目前为止，还没有疾病修饰 为AD/ADRD患者提供治疗选择，使其成为研究界的高度优先事项。的 本提案的目的是提供来自死后AD/ADRD供体的生物标本，以及非 AD/ADRD人类生物标本资源（ADBR）的患病对照供体，适合支持 处理外地高度优先需求和关键问题的关键调查线。 OMB编号0925-0001/0002（2018年1月批准至2020年3月31日修订版）页码续页格式页码